Ask the Expert: What Are Some Considerations When First Treating Prostate Cancer Patients?

Posted by Daniel P. Petrylak, MD | Oct 2017

Daniel P. Petrylak, MD, Yale Cancer Center, New Haven, Connecticut, discusses some of the steps when first treating advanced prostate cancer patients.

Interview produced by Prostatepedia

Keywords: biomarkers, prostate cancer, AR-V7, BRCA, androgen receptor

About The Author

Daniel P. Petrylak, MD

Daniel P. Petrylak, MD, is currently Director of Genitourinary Oncology, Professor of Medicine and Urology, Co-Leader of Cancer Signaling Networks, and Co-Director of the Signal Transduction Program at Yale University Cancer Center in New Haven, Connecticut. He is a recognized international leader in the urology field. He earned his MD at Case Western Reserve University School of Medicine in Cleveland Ohio. He then went on to complete his Internal Medicine Residency at Albert Einstein College of Medicine/Jacobi Medical Center in the Bronx, and his fellowship at Memorial Sloan Kettering Cancer Center in New York. Dr. Petrylak has served as principal investigator (PI) or co-PI on several SWOG clinical trials for genitourinary cancers. Most notably, he served as the PI for a randomized trial that led to the FDA approval of docetaxel in hormone refractory prostate cancer. He also helped to design and served as PI for the SPARC trial, an international registration trial evaluating satraplatin as a second-line therapy for hormone refractory prostate cancer. Dr. Petrylak served on the program committees for the annual meetings of the American Urological Association from 2003-2011, and for the American Society of Clinical Oncology from 1995-1997 and 2001-2003. He also has served as a committee member for the Devices and Immunologicals section of the FDA. He has published extensively in the New England Journal of Medicine, Journal of Clinical Oncology, Journal of the National Cancer Institute, Cancer Research, and Clinical Cancer Research.

Join the GRU Community

- Why Join? -

CARDEN JENNINGS PUBLISHING CO., LTD.

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

PDF Embedder Test Jan 2022
Genetic Testing and Prostate Cancer – Welcome Jan 2022
Current Status of PSMA Diagnostics Aug 2021
Genetic Testing and Prostate Cancer Aug 2021
What’s New in Active Surveillance for Prostate Cancer in 2021 Aug 2021

Ask the Expert: What Are Some Considerations When First Treating Prostate Cancer Patients?

About The Author

Daniel P. Petrylak, MD

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

Exercise & Wellness

Ask the Expert: What Are Some Considerations When First Treating Prostate Cancer Patients?

About The Author

Daniel P. Petrylak, MD

Related Posts

Is Focal Ablation of Prostate Cancer Ready for Prime Time?

What Tools Can Be Used to Predict Who Will Respond to Certain Prostate Cancer Drugs?

Prostate Cancer: A Review of Current Prostate Cancer Markers and a Novel Model of Organization

Prostate Cancer Treatment: From Monotherapy to Sequencing

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard – Your Courses

Recent Updates

Exercise & Wellness

– Account Dashboard
– Your Courses